Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pollinex Quattro Grass long-term placebo-controlled pediatric trial for grass pollen allergic rhinitis
2023-508520-36-00Phase 3Authorised
- Sponsor
- Allergy Therapeutics PLC
- Start
- Sep 2024
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) and allergic rhinoconjunctivitis (ARC) comparing Pollinex Quattro Grass with Placebo (2 arms). Planned start Sep 2024; status: authorised.
02
Drugs
Grass MATA MPL
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2023-508520-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508520-36-00.